308.31
2.74%
+8.23
Icon Plc stock is currently priced at $308.31, with a 24-hour trading volume of 714.48K.
It has seen a +2.74% increased in the last 24 hours and a -6.55% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $305.1 pivot point. If it approaches the $313.5 resistance level, significant changes may occur.
Previous Close:
$300.08
Open:
$302.85
24h Volume:
714.48K
Market Cap:
$25.49B
Revenue:
$8.23B
Net Income/Loss:
$683.12M
P/E Ratio:
49.73
EPS:
6.2
Net Cash Flow:
$1.17B
1W Performance:
+6.97%
1M Performance:
-6.55%
6M Performance:
+28.16%
1Y Performance:
+53.48%
Icon Plc Stock (ICLR) Company Profile
Name
Icon Plc
Sector
Industry
Phone
353 1 291 2000
Address
South County Business Park, Leopardstown, Dublin
Icon Plc Stock (ICLR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-15-23 | Initiated | Truist | Buy |
Sep-13-23 | Initiated | TD Cowen | Outperform |
Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
Sep-07-22 | Initiated | UBS | Buy |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
May-24-22 | Initiated | Guggenheim | Buy |
Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
Jul-14-21 | Initiated | Citigroup | Neutral |
Apr-13-21 | Resumed | BofA Securities | Neutral |
Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Mar-03-21 | Initiated | Barclays | Equal Weight |
Mar-01-21 | Upgrade | UBS | Neutral → Buy |
Feb-26-21 | Upgrade | Truist | Hold → Buy |
Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-02-20 | Initiated | Deutsche Bank | Hold |
Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Neutral |
Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Jul-26-19 | Upgrade | UBS | Sell → Neutral |
Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-09-18 | Initiated | UBS | Sell |
Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-15-18 | Reiterated | Mizuho | Neutral |
Jan-19-18 | Initiated | Evercore ISI | Outperform |
Oct-27-17 | Reiterated | Barclays | Equal Weight |
Sep-11-17 | Initiated | BofA/Merrill | Buy |
Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
Jul-27-17 | Reiterated | Mizuho | Neutral |
Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
Zacks Investment Research
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
Zacks Investment Research
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
Zacks Investment Research
Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Icon Plc Stock (ICLR) Financials Data
Icon Plc (ICLR) Revenue 2024
ICLR reported a revenue (TTM) of $8.23 billion for the quarter ending March 31, 2024, a +5.29% rise year-over-year.
Icon Plc (ICLR) Net Income 2024
ICLR net income (TTM) was $683.12 million for the quarter ending March 31, 2024, a +33.95% increase year-over-year.
Icon Plc (ICLR) Cash Flow 2024
ICLR recorded a free cash flow (TTM) of $1.17 billion for the quarter ending March 31, 2024, a +223.06% increase year-over-year.
Icon Plc (ICLR) Earnings per Share 2024
ICLR earnings per share (TTM) was $8.22 for the quarter ending March 31, 2024, a +33.01% growth year-over-year.
About Icon Plc
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Cap:
|
Volume (24h):